Boundless Bio Reports First Quarter 2025 Financial Results and Business Highlights

Core Insights - Boundless Bio is focused on developing therapies for oncogene-amplified cancers, with ongoing clinical trials and promising data expected in the near future [2][3][7] Research and Development Highlights - The BBI-355 Phase 1/2 POTENTIATE trial is currently enrolling patients, with initial proof-of-concept data anticipated in the second half of 2025 [1][3] - A novel Kinesin program is on track for a development candidate nomination by mid-2025, with an IND filing planned for the first half of 2026 [1][4] - Preclinical data for the RNR inhibitor BBI-825 suggests it may delay or prevent acquired resistance in colorectal cancer models [5] Financial Performance - As of March 31, 2025, the company reported a cash position of $138.3 million, providing operational runway into 2027 [1][8] - Research and Development expenses for Q1 2025 were $12.1 million, a decrease from $13.1 million in Q1 2024 [8][12] - General and Administrative expenses increased to $5.2 million in Q1 2025 from $3.8 million in Q1 2024 [8][12] - The net loss for Q1 2025 was $15.8 million, compared to a net loss of $15.4 million in the same period of 2024 [8][12]